These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Successful alternate day guanidine therapy following guanidine-induced neutropenia in the Lambert-Eaton myasthenic syndrome. Silbert PL; Hankey GJ; Barr AL Muscle Nerve; 1990 Apr; 13(4):360-1. PubMed ID: 2355949 [No Abstract] [Full Text] [Related]
8. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. ; Jacob S; Muppidi S; Guidon A; Guptill J; Hehir M; Howard JF; Illa I; Mantegazza R; Murai H; Utsugisawa K; Vissing J; Wiendl H; Nowak RJ J Neurol Sci; 2020 May; 412():116803. PubMed ID: 32247193 [No Abstract] [Full Text] [Related]
9. [Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome]. Boutin E; Rey C; Romeu M; Pouget J; Franques J Rev Med Interne; 2013 Aug; 34(8):493-6. PubMed ID: 23759215 [TBL] [Abstract][Full Text] [Related]
10. [Cyclosporin A in the treatment of Eaton-Lambert myasthenic syndrome]. Yuste Ara JR; Beloqui Ruiz O; Artieda Gonzalez-Granda J; Herrero Santos JI; De la Peña Fernandez A; Prieto Valtueña J An Med Interna; 1996 Jan; 13(1):25-6. PubMed ID: 8679819 [TBL] [Abstract][Full Text] [Related]
11. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Oh SJ; Kim DS; Head TC; Claussen GC Muscle Nerve; 1997 Sep; 20(9):1146-52. PubMed ID: 9270671 [TBL] [Abstract][Full Text] [Related]
12. Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy. Cooke JD; Hefter H; Brown SH; Toyka KV; Freund HJ Electromyogr Clin Neurophysiol; 1994 Mar; 34(2):87-93. PubMed ID: 8187683 [No Abstract] [Full Text] [Related]
13. Lambert-Eaton myasthenic syndrome in childhood. Kostera-Pruszczyk A; Ryniewicz B; Rowinska-Marcinska K; Dutkiewicz M; Kamińska A Eur J Paediatr Neurol; 2009 Mar; 13(2):194-6. PubMed ID: 18585938 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic approaches to Lambert-Eaton myasthenic syndrome in the intra-individual comparison. Jost WH; Mielke U; Schimrigk K Wien Klin Wochenschr; 1991; 103(20):629-32. PubMed ID: 1763511 [TBL] [Abstract][Full Text] [Related]
17. [Treatment of the paraneoplastic Lambert-Eaton syndrome]. Courau E; Westeel V; Jacoulet P; Depierre A Rev Pneumol Clin; 1998 May; 54(2):65-70. PubMed ID: 9769989 [TBL] [Abstract][Full Text] [Related]
18. Non-paraneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases. Lorenzoni PJ; Scola RH; Kay CS; Parolin SF; Werneck LC Arq Neuropsiquiatr; 2010 Dec; 68(6):849-54. PubMed ID: 21243240 [TBL] [Abstract][Full Text] [Related]
19. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Tim RW; Massey JM; Sanders DB Ann N Y Acad Sci; 1998 May; 841():823-6. PubMed ID: 9668336 [No Abstract] [Full Text] [Related]